Heart failure & cardiomyopathies
Impella device in fulminant myocarditis: Japanese Registry for Percutaneous Ventricular Assist Device (J-PVAD) registry analysis on outcomes and adverse events
Authors' conclusion
Impella's use in fulminant myocarditis demonstrates encouraging short-term outcomes, albeit with significant adverse events.
Study context
- Population
- Patients with fulminant myocarditis treated with Impella, J-PVAD registry, February 2020 to December 2021
- Participants
- 269 patients
- Exposure
- ECPELLA vs Impella standalone
- ECPELLAn = 162
- Impella standalonen = 107
- Outcome
- 30-day mortality
- Follow-up
- 30 days
Main finding
As reported in the abstract
30-day survival
- Overall 30-day survival
- 74.3%
Observational data: associations, not effects.
Further findings
Predictors of adverse events (Cox regression)
- Lower eGFR and pre-Impella SBP increased adverse event risk; Swan-Ganz catheterization use reduced it
Safety
- Any adverse event
- 48.7%
- Bleeding
- 32.0%
- Deteriorating renal function
- 8.6%
Original publication
Impella device in fulminant myocarditis: Japanese Registry for Percutaneous Ventricular Assist Device (J-PVAD) registry analysis on outcomes and adverse events. Eur Heart J Acute Cardiovasc Care. Published 4 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →